Compare CYTK & AXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | AXS |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.2B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | AXS |
|---|---|---|
| Price | $62.50 | $99.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | $82.38 | ★ $121.57 |
| AVG Volume (30 Days) | ★ 2.2M | 582.5K |
| Earning Date | 02-26-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | N/A | ★ 68.27 |
| EPS | N/A | ★ 12.10 |
| Revenue | $87,211,000.00 | ★ $6,301,015,000.00 |
| Revenue This Year | $339.72 | $6.62 |
| Revenue Next Year | $79.08 | $8.58 |
| P/E Ratio | ★ N/A | $8.26 |
| Revenue Growth | ★ 2609.26 | 5.59 |
| 52 Week Low | $29.31 | $84.81 |
| 52 Week High | $70.98 | $110.34 |
| Indicator | CYTK | AXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 36.88 |
| Support Level | $60.30 | $98.32 |
| Resistance Level | $65.08 | $101.14 |
| Average True Range (ATR) | 2.91 | 1.91 |
| MACD | -0.01 | -0.97 |
| Stochastic Oscillator | 45.74 | 11.48 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.